RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial.

Clin Transl Radiat Oncol · 2020 · PMC7218223 · PMID 32420463

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the PACIFIC randomized phase III trial examining the possible benefit of RCT combination with Durvalumab compared with RCT plus placebo in patients with NSCLC, a highly significant improvement in the PFS rate of approximately 20% after 12 months and 18 months was reported [19] .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.